SAG
LENZ

SageView Advisory Group’s LENZ Therapeutics LENZ Stock Holding History

SageView Advisory Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$112 Buy
+7
New +$204 ﹤0.01% 2535

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

SageView Advisory Group's LENZ Position: Q4 2025 in Review

SageView Advisory Group opened a new position in LENZ Therapeutics (LENZ) in Q4 2025: 7 shares worth $112. The stake represents ﹤0.01% of the portfolio and ranks #2535 among its holdings.

160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • SageView Advisory Group held 7 shares of LENZ Therapeutics worth $112 as of Q4 2025.
  • LENZ Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • LENZ Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2535 holding.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.